DoorDash aims to raise $3.14 billion in much-awaited IPO

iwano@_84

(Reuters) – Food delivery startup DoorDash Inc said on Friday it now expects to raise up to $3.14 billion in its U.S. initial public offering (IPO) after lifting its pricing range, signaling a frenzied interest from investors. © Reuters/CARLO ALLEGRI FILE PHOTO: A delivery person for Doordash rides his bike […]

(Reuters) – Food delivery startup DoorDash Inc said on Friday it now expects to raise up to $3.14 billion in its U.S. initial public offering (IPO) after lifting its pricing range, signaling a frenzied interest from investors.





© Reuters/CARLO ALLEGRI
FILE PHOTO: A delivery person for Doordash rides his bike in the rain in the Manhattan borough of New York City

DoorDash, the biggest U.S. third-party delivery company for restaurants, plans to sell 33 million shares at between $90 and $95 apiece, it said in a regulatory filing https://www.sec.gov/Archives/edgar/data/1792789/000119312520309968/d752207ds1a.htm. It had earlier targeted a price range of between $75 and $85 per share.

Founded in 2013, DoorDash is backed by the Vision Fund managed by Japanese tech giant SoftBank Group Corp, venture capital firm Sequoia Capital and the Government of Singapore Investment Corp (GIC), Singapore’s sovereign wealth fund.

Video: DoorDash kicks off IPO roadshow with updated filing (CNBC)

Its market capitalization at the top end of the range would be around $30 billion.

San Francisco-based DoorDash plans to list its shares on the New York Stock Exchange under the ticker “DASH” this month. It had confidentially filed for an IPO in February.

DoorDash and rivals Uber Eats, Grubhub Inc and Postmates Inc have benefited from a surge in demand for food delivery services due to widespread COVID-19 restrictions.

Goldman Sachs and J.P. Morgan are the lead underwriters for the offering.

(Reporting by Noor Zainab Hussain in Bengaluru; Editing by Anil D’Silva)

Continue Reading

Source Article

Next Post

UCB Demonstrates Commitment to Science and Discovery Across Its Epilepsy Portfolio at the American Epilepsy Society's Virtual Event AES2020

ATLANTA, Dec. 4, 2020 /PRNewswire/ — UCB today announced that 15 scientific posters will be presented at the upcoming American Epilepsy Society’s all new virtual event, AES2020, December 4-8, 2020. The scientific program features the latest research on VIMPAT in primary generalized tonic-clonic seizures (PGTCS). VIMPAT was just recently approved […]

Subscribe US Now

Exit mobile version